An article questioning the huge price difference in the cost of cancer drugs between US and some developing countries and offering relatively simple risk-reduction strategies. Gleevec, a drug used to treat leukemia, costs $70,000 a year in the US but only $2,500 in India. This costly gap exists thanks to US patents that prevent competitors from making and selling lower cost ... Continue Reading